# CROWN (NCT03052608)

> A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03052608
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Pfizer
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Lorlatinib; Crizotinib
- Enrollment: 296
- Primary outcome: Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) Assessment

## Indexed commentary on CROWN so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 13
- Bluesky threads: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=crown-nct03052608

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03052608", "email": "<work email>"}; the inbox owner confirms by the emailed link.